

Year-end report
2014



Research and development of protein-based
therapeutics to improve the lives of patients
with severe diseases



Contents

CEO Statement	3
About Affibody	4
Operational review	5
Financial Summary	6
Financial statements for the group	10
Statement of comprehensive income	10
Balance sheet	11
Changes in Equity	12
Cash flow statement	13
Financial information for the Parent company	14
Statement of Comprehensive Income	14
Balance sheet	15
Changes in Equity	16
Cash flow statement	17



Affibody Medical AB (publ) (556714-5601)
Gunnar Asplunds Allé 24
SE-171 63 Solna, Sweden

E-mail: reception@affibody.com
Phone: +46 (0) 8 59 88 38 00

www.affibody.com

Key events during the Fourth Quarter 2014

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Year-end Report for 2014.

Financial Highlights

- » Revenue for the 4th quarter 2014 was SEK 24.2 (22.8) million, and for the full year 57.6 (68.2) million
- » Operating result for the period amounted to SEK 8.5 (1.7) million, and for the full year to 5.3 (8.5) million
- » EBITDA for the period amounted to SEK 8.6 (1.8) million, and for the full year to 5.7 (8.7) million
- » Net result for the period amounted to SEK 7.9 (0.9) million, and for the full year to 3.7 (6.6) million
- » Cash flow for the period was SEK 9.9 (12.5) million, and for the full year 2.8 (11.8) million
- » Cash and cash equivalents at the end of the period amounted to SEK 35.9.0 (33.1) million

Significant events during the fourth quarter

- » In October 2014, Sobi decided to place the phase 1 study of SOBI002 on clinical hold as adverse events were observed in the first-in-human study. All subjects that have been dosed with SOBI002 are well. Sobi is now working to understand these adverse events.
- » In November 2014 Nordic Nanovector ASA and Affibody AB announced that the companies have entered into a three-year collaborative research agreement to discover and develop new advanced radio-immunotherapies (RIT) for multiple myeloma, a collaboration backed by a Eurostars grant.

Other significant events during 2014

- » The first patient was included in a PET imaging study of HER2 expression in breast cancer at Herlev University Hospital
- » Investor AB acquired all HealthCap’s shares in Affibody

Significant events after the end of the reporting period

- » No significant events were reported after the end of the reporting period

(SEKk)	2014 (3m)	2013 (3m)	2014 (12m)	2013 (12m)
Revenue	24 151	22 814	57 623	68 183
Operating result	8 494	1 671	5 270	8 484
Operating margin	35%	7%	9%	12%
Net result	7 887	904	3 730	6 629

CEO Statement

The last few years have been phenomenal for the biotech industry. In the future we can look back at a year where there were more IPOs done than during the peak of the genomics-boom in 2000 and that 2014 has been reported to be the best M&A exit year over the last ten years. The driver behind these returns and public financings can to some extent be found in new technologies, such as CAR-T's that uses the patient's own immune system to treat cancer, and new drugs, such as Sovaldi, a drug which for the first time could offer a cure for Hepatitis C.

Part of the explanation why these breakthroughs emerge now can probably be found in a recent report the Bio Industry Organization (BIO) released outlining how private funding in the biotech industry has grown substantially over the last few years. This funding has been primarily directed to novel drug R&D which quite naturally is the driver for new breakthroughs. From Affibody's perspective it is interesting to note that platform and biologics companies have received more funding in the last five year period than in the five year period before.

A consequence of the rich source of capital in recent years many companies have a multitude of options ahead including continuing as a stand-alone entity to create more value for its shareholders. We continue to believe that the key for Affibody in the coming period is to continue the transformation of our company from a preclinical company to a clinical operating company with multiple proprietary assets in the clinic. By taking this step we can continue to deliver value to our shareholders for the foreseeable future. As I have communicated before we will probably be able to fund part of this transformation using our cash and cash-flow but to fully maximize the value of our platform in this respect it is likely that external funding is needed.

In closing I would like to thank my colleagues at Affibody for another great year. It has been a year in which we have pushed our company substantially forward. This push coupled with the investments we have made will yield results in the coming years.

Solna in February 2015

David Bejker
President and CEO



We continue to believe that the key for Affibody in the coming period is to continue the transformation of our company from a preclinical company to a clinical operating company with multiple proprietary assets in the clinic.

David Bejker
President and CEO

Our mission is to improve the lives of patients with serious diseases by being a research-driven company with a long-term commitment to development of protein-based drugs.

About Affibody

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody[®] molecules and Albumod[™].

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod[™], for outlicensing.

Affibody has ongoing commercial relationships with several companies such as Algeta, Amylin, Swedish Orphan Biovitrum, GE Healthcare, Daewoong, Daiichi Sankyo, Nordic Nanovector and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Solna, Sweden. The major shareholder in the company is Investor AB. Further information can be found at: www.affibody.com

Mission

Our mission is to improve the lives of patients with serious diseases by being a research-driven company with a long-term commitment to development of protein-based drugs.

Business Model

Affibody shall operate a self-sustaining business that develops and commercializes products based on the company's technology platforms in collaboration with other companies for considerations including licensing- and royalty fees.

Business goal

Affibody's goals are to:

- » Annually enter into one new partnership agreement.
- » Annually develop one internal project to candidate drug.

Strategy

Affibody prioritizes a partner-based development model that reduces the financial exposure. To increase the value of licensing agreements, Affibody also runs its own development projects in early clinical phases. Operations are conducted by highly qualified resources in research and development and are based on the company's proprietary technology platforms.

Operational review

Products on the market

GE Healthcare

The product MabSelect Sure™ was launched by GE Healthcare Bio-Sciences AB in 2004, as a result of a collaboration with Affibody for the development of affinity ligands for large scale affinity purification. The product generates royalties and constitutes Affibody's largest revenue source. The product generates royalties until 2019 and contributes to that Affibody, unlike many other biotech companies, conducts operations that can generate balanced cash flows.

ThermoFisher

Thermo Fisher (formerly Finnzymes Oy) and Affibody has collaborated on the development of an Affibody® molecule for a hot start PCR application. The collaboration resulted in the product Phusion™ Hot Start High-Fidelity DNA Polymerase, launched by Finnzymes Oy in 2006. This product generates royalties until the end of 2015.

Projects in Clinical Development

GE Healthcare

In 2012 Affibody signed an agreement with GE Healthcare for collaboration on the development of an agent for HER2-targeted imaging of breast and gastric cancer. Under the collaboration, Affibody conducts early clinical trials together with academic groups.

Sobi

In 2009, Affibody signed an agreement with Sobi. The collaboration aims to develop new targeted therapies for inflammatory and autoimmune diseases. Sobi has gained access to Affibody's both technology platforms for the development of drugs against a defined target. In November 2013, Sobi announced its intention to bring a novel investigational biopharmaceutical drug candidate, SOBI002 into a phase I trial. SOBI002 works as a potent and selective inhibitor of complement protein C5, a key protein in human immunological and inflammatory processes and central to a number of important diseases. In October 2014, Sobi decided to place the phase I study of SOBI002 on clinical hold as adverse events were observed in the first-in-human study. All subjects that have been dosed with SOBI002 are well. Sobi is now working to understand these adverse events.

Projects in preclinical research and development

Algeta

In 2011 Algeta ASA acquired a license to Affibody's technology platforms to develop new tumor targeting drug candidates based on the alpha emitter Thorium-227.

Amylin

In 2010 Affibody signed a license agreement with Amylin regarding the use of Albumod™. The technology will be applied to a number of molecules from Amylin's library of proprietary compounds to enhance the efficacy by extending their half-life in the circulation.

Daewoong

In 2013 Affibody signed a license agreement with Daewoong regarding the use of Albumod™. The technology will be applied to increase the efficacy of one of Daewoong's patented compounds by prolonging the half-life in the circulation.

Daiichi Sankyo

In 2013 Affibody signed a license agreement with Daiichi Sankyo regarding the use of Albumod™. The technology will be applied to increase the efficacy of one of Daiichi Sankyo's patented compounds by prolonging the half-life in the circulation.

Nordic Nanovector

In November 2014 Nordic Nanovector ASA and Affibody AB announced that the companies have entered into a three-year collaborative research agreement to discover and develop new advanced radio-immunotherapies (RIT) for multiple myeloma, a collaboration backed by a Eurostars grant.

Sobi

In 2012 Affibody signed another agreement with Sobi in order to develop new treatments for interleukin-1 (IL-1)-driven inflammatory diseases. The agreement includes an initial two year period during which Sobi has an option to enter into a license agreement with worldwide exclusive rights to any or all of the development projects.

Financial summary - Fourth quarter 2014

Significant events during the reporting period and after close of the reporting period

The ongoing partnerships have continued to develop well during the reporting period. An Annual General Meeting (EGM), held on May 8 elected Håkan Åström, Jakob Lindberg, Mathias Uhlén and Jonathan Knowles as Directors of the Board. Also during the period, the first patient was included in a PET imaging study of HER2 expression in breast cancer at Herlev University Hospital, a study that will expand on the previous clinical experience with ABY-025 imaging and investigate HER2 expression in breast cancer patients before and after treatment. In October 2014, Sobi decided to place the phase 1 study of SOBI002 on clinical hold as adverse events were observed in the first-in-human study. All subjects that have been dosed with SOBI002 are well. Sobi is now working to understand these adverse events.

Revenue

Revenue for the quarter amounted to SEK 24.2 (22.8) million and for the full year to SEK 57.6 (68.2) million where the majority of the revenue comes from royalties and research payments from commercial partners.

Operating Costs

Total operating costs for the quarter amounted to SEK 15.7 (21.1) million and for the full year to SEK 52.4 (56.7) million. The costs consisted of research and development costs of SEK 12.5 (16.0) million for the quarter and SEK 41.4 (43.4) million for the

full year. Administrative costs amounted to SEK 2.5 (4.8) million for the quarter and to SEK 9.1 (15.0) million for the full year and marketing and sales costs amounted to SEK 0.6 (0.3) million for the quarter and to SEK 1.8 (1.3) million for the full year. Depreciation of fixed assets amounted to SEK 0.1 (0.1) million for the quarter and to SEK 0.4 (0.2) million for the full year and were related to laboratory equipment. Of the operating costs, SEK 0.6 (1.2) million for the quarter and SEK 2.5 (3.6) million for the full year were related to the incentive programs.

Operating Result

The operating result for the quarter amounted to SEK 8.5 (1.7) million and for the full year to SEK 5.3 (8.5) million.

Financial items

Financial income for the quarter amounted to SEK 0.0 (0.1) million and for the full year to SEK 0.3 (0.3) million and consisted of interest income. Financial costs for the quarter amounted to SEK 0.6 (0.9) million and for the full year to SEK 1.8 (2.2) million and consisted of considerations to a partner for the prepayment of royalties.

Taxes

No corporate income tax was reported during the period (-). The Group's unutilized tax losses have not been assigned any value in the balance sheet as they are not expected to be utilized within the conventional period.

Net Result

Net result for the quarter amounted to SEK 7.9 (0.9) million and for the full year to SEK 3.7 (6.6) million.

Cash Flow

Cash flow from current operations, before changes in working capital, amounted to SEK 8.7 (1.9) million and for the full year to SEK 6.0 (10.4) million including non-cash items of SEK 0.8 (1.0) million and for the full year to SEK 2.2 (3.8) million mainly related to the depreciation of tangible assets and employee stock ownership plans. The cash flow from working capital changes for the period amounted to SEK 1.3 (10.7) million and for the full year to SEK -3.6 (2.9) million. Capital expenditure for the quarter amounted to SEK 0.0 (0.1) million and for the full year to SEK 0.3 (1.5) million. Proceeds from a new issue of shares, related to exercise of Employee Stock Option Programs (ESOPs) amounted to SEK - (-) million and for the full year to SEK 0.8 (-) million. Cash flow for the quarter amounted to SEK 9.9 (12.5) million and for the full year to SEK 2.8 (11.8) million.

Financial Position

As of December 31, 2014, cash amounted to SEK 35.9 (33.1) million. The equity ratio at the end of the quarter was 71 (61) %.

Shareholders' Equity

Total equity in the Group as of December 31, 2014 was SEK 36.9 (30.9) million.

Parent company

Affibody Medical AB's revenue for the full year amounted to SEK 4.8 (5.3) million. The costs, mainly consisting of administrative costs in relation to management and financing activities amounted for the full year to -6.6 (-11.6) million. Net result amounted to SEK -1.7 (-6.2) million. Cash and cash equivalents as of December 31, 2014 amounted to SEK 7.7 (7.6) million and the equity amounted to 245.6 (246.5) million.

Employees

Per December 31, 2014 the number of employees amounted to 24 (21).

Incentive program

During the second quarter, as a consequence of Investor AB's acquisition of Health Cap's shares in Affibody, seven of the nine outstanding Employee Stock Option Programs (ESOPs) were exercised. Of the programs' 3 858 104 ESOPs, 3 077 710 were exercised in a cash less transaction and 779 680 for subscription of 38 984 new shares. Per the end of the reporting period, a total of 12 800 000 Employee Stock Options (ESOPs) were outstanding. Twenty options give the holder a right to subscribe to one new share in Affibody Medical. Affibody holds a total of 16 250 000 warrants of which 12 800 000 are issued to ensure delivery of shares under the employee stock option above and the remainder for hedging of social security contributions and other costs related to the programs. Twenty warrants entitle the holder

to subscribe for one new ordinary share. For more information about incentive programs see the Annual Report for 2013.

Significant risks and uncertainties

No changes in the company's risk assessment have taken place during the period. A detailed presentation of significant risks and uncertainties is available in the Annual Report 2013.

General information

Affibody Medical AB (previously Affibody Holding AB) (publ) (registration number 556714-5601) is a public limited company with registered office in Stockholm in Sweden. "Affibody" and "the Company" refers to Affibody Medical AB, and where appropriate, including subsidiaries.

AGM

An Annual General Meeting (EGM) held on May 8, 2014 elected Håkan Åström, Jakob Lindberg, Mathias Uhlén and Jonathan Knowles as Directors of the Board.

The share

As of December 31, 2014 the registered share capital amounted to 52 899 769 SEK divided into 10 579 954 shares. Together with the warrants held, the total number of shares, after full exercise of these warrants, amounts to 11 392 454. Affibody Medical AB has only one share-class and the shares carry one vote each and are entitled to equal shares of distributable earnings.

Accounting principles

This report has been prepared in accordance with IAS 34, Interim Financial Reporting. The accounting principles are in accordance with International Financial Reporting Standards (IFRS), and the EU-approved interpretations of those standards, International Financial Reporting Interpretations Committee (IFRIC) and Chapter 9 of the Annual Accounts Act. This report has been prepared using the same accounting policies and methods of computation as the Annual Report for 2013. No new IFRS standards effective from 2014 will have an effect on Affibody's financial statements. The extent and nature of financial assets and liabilities are essentially the same as at 31 December 2013. Similar to what was the case at the end of 2013, the recorded values are the same as fair values. The Parent Company follows the Swedish Financial Reporting Board and the recommendation RFR 2, meaning that the parent company, in the reporting of the legal entity, shall apply all EU-approved IFRS and statements as far as possible within the framework of the Annual Accounts Act, the Pension Obligations Vesting Act and considering the relationship between accounting and taxation.

Forward-looking statement

This interim report includes statements that are forward-looking. Actual results may differ from those stated. Internal factors such as the successful management of research and intellectual property rights may affect future results. There are also external conditions such as the economic climate, political changes and competing research that may affect Affibody's results.

Other

Amounts are expressed in SEKk (thousands Swedish kronor) unless otherwise stated. Figures in parentheses refer to the corresponding period last year. The Board of Directors and the CEO of Affibody Medical provide their assurance that the interim report provides a fair and true overview of the parent company's and the group's operations, financial position and results, and describes material risks and uncertainties faced by the parent company and the companies in the group. See under the heading "Significant risks and uncertainties" and in other information provided for a description of the operational risks.

Stockholm on February 27, 2015

Håkan Åström **Jonathan Knowles**
Chairman Board Member

Mathias Uhlén **Jakob Lindberg**
Board Member Board Member

David Bejker
President and CEO

This report has not been subject to review by the company's auditor.

For further information please contact:

David Bejker, CEO, Phone: +46 706 454 948

Johan Stuart, CFO, Phone: +46 706 644 096

Financial Calender

- » The interim report for January-March 2015 will be published on May 20, 2015.
- » The interim report for January-June 2015 will be published on August 21, 2015.
- » The interim report for January-September 2015 will be published on November 20, 2015.

Affibody Medical AB (publ)

Gunnar Asplunds Allé 24

171 63 Solna, Sweden

Phone: +46 8 59 88 38 00

www.affibody.com

Reg 556714-5601





Financial statements for the group

Income Statement

(SEKk)	Oct - Dec 2014	Oct - Dec 2013	Jan - Dec 2014	Jan - Dec 2013
Sales	23 071	22 714	55 509	67 594
Other revenue	1 080	100	2 114	589
Total	24 151	22 814	57 623	68 183
Operating costs				
Marketing and sales costs	-596	-309	-1 843	-1 262
Administrative costs	-2 538	-4 835	-9 126	-15 022
Research and development costs	-12 524	-16 000	-41 384	-43 415
Total operating costs	-15 658	-21 143	-52 353	-59 699
Operating profit / loss	8 494	1 671	5 270	8 484
Net financial items				
Other interest income and similar profit/loss items	33	96	294	338
Other interest expense and similar profit/loss items	-640	-863	-1 834	-2 194
Total net financial items	-607	-767	-1 540	-1 855
Profit / loss after financial items	7 887	904	3 730	6 629
Income tax	-	-	-	-
Net result	7 887	904	3 730	6 629
Other comprehensive income	-	-	-	-
Comprehensive income	7 887	904	3 730	6 629

The result for the period is in total attributable to the parent company's shareholders.

Consolidated balance sheet

(SEKk)	2014-12-31	2013-12-31
ASSETS		
Non-current assets		
Property, plant and equipment	1 507	1 617
Total non-current assets	1 507	1 617
Current assets		
<i>Other receivables</i>		
Accounts receivable	1 533	4 281
Other receivables	171	338
Prepaid expenses and accrued income	12 864	11 077
Total receivables	14 568	15 696
Cash and cash equivalents	35 919	33 072
Total current assets	50 488	48 768
Total assets	51 995	50 385

(SEKk)	2014-12-31	2013-12-31
EQUITY AND LIABILITIES		
Equity		
Share capital	52 900	52 705
Other capital contribution	576 706	574 651
Accumulated result including result for the period	-592 745	-596 475
Total equity	36 861	30 881
Non-current liabilities		
Provisions	2 665	2 342
Total non-current liabilities	2 665	2 342
Current liabilities		
Accounts payable	5 203	6 709
Other payables	1 325	2 818
Accrued expenses and deferred income	5 941	7 635
Total current liabilities	12 469	17 162
Total equity and liabilities	51 995	50 385
Pledged assets	-	-
Contingent liabilities	-	-

Consolidated changes in Equity

(SEKk)	Share capital	Other capital contribution	Accumulated losses	Total
Closing balance Dec 31 2012	52 705	571 820	-603 104	21 421
Net result Jan-Dec 2013	-	-	6 629	6 629
Employee StockOwnership Plan	-	2 831	-	2 831
Closing balance Dec 31 2013	52 705	574 651	-596 475	30 881
Closing balance Dec 31 2013	52 705	574 651	-596 475	30 881
Net result Jan-Dec 2014	-	-	3 730	3 730
Employee StockOwnership Plan	-	1 471	-	1 471
New Share issue	195	585	-	780
Closing balance Dec 31 2014	52 900	576 706	-592 745	36 861

The equity is in total attributable to the parent company's shareholders.

Cash Flow Statement

(SEKk)	Oct - Dec 2014	Oct - Dec 2013	Jan - Dec 2014	Jan - Dec 2013
Current operations				
Profit / loss after financial items	7 887	904	3 730	6 629
Adjustments for non-cash flow items				
Depreciation	116	97	442	238
Other non-cash flow items	681	937	1 793	3 570
Cash flow from current operations before income tax	8 683	1 939	5 965	10 437
Income tax paid	-	-	-	-
Cash flow from current operations before changes in working capital	8 683	1 939	5 965	10 437
Cash flow from working capital changes				
Change in trade, other receivables and current assets	-4 366	5 190	1 128	-5 405
Change in trade, other payables and other current liabilities	5 678	5 539	-4 693	8 332
Cash flow from current operations	9 995	12 667	2 400	13 363
Investment activities				
Investments in property, plant and equipment	-46	-147	-332	-1 536
Sale of property, plant and equipment	-	-	-	-
Cash flow from investment activities	-46	-147	-332	-1 536
Financing activities				
New issue	-	-	780	-
Loan from shareholders	-	-	-	-
Transaction costs share issue	-	-	-	-
Cash flow from financing activities	-	-	780	-
Cash flow for the period	9 949	12 519	2 847	11 827
Cash and cash equivalents at beginning of period	25 970	20 552	33 072	21 245
Cash and cash equivalents at end of period	35 919	33 072	35 919	33 072

Financial statements for the parent company

Income Statement

(SEKk)	Oct - Dec 2014	Oct - Dec 2013	Jan - Dec 2014	Jan - Dec 2013
Revenue	1 200	1 200	4 800	5 289
Total	1 200	1 200	4 800	5 289
Operating expenses				
Marketing and sales costs	-	-	-	-
Administrative costs	-1 763	-3 969	-6 631	-11 650
Research and development costs	-	-	-	-
Total operating expenses	-1 763	-3 969	-6 631	-11 650
Operating profit / loss	-563	-2 769	-1 831	-6 360
Net financial items				
Other interest income and similar profit/loss items	16	26	116	126
Other interest expense and similar profit/loss items	-	-0	-1	-1
Total net financial items	16	26	115	126
Profit / loss after financial items	-547	-2 743	-1 716	-6 235
Income tax	-	-	-	-
Net loss	-547	-2 743	-1 716	-6 235
Other comprehensive income	-	-	-	-
Comprehensive income	-547	-2 743	-1 716	-6 235

Parent company balance sheet

(SEKk)	2014-12-31	2013-12-31
ASSETS		
Non-current assets		
Shares in group companies	220 200	220 200
Total non-current assets	220 200	220 200
Current assets		
Other receivables		
Accounts receivable	-	-
Other receivables	82	96
Receivables from group companies	20 047	23 275
Total receivables	20 129	23 371
Cash and cash equivalents	7 652	7 595
Total current assets	27 781	30 967
TOTAL ASSETS	247 981	251 167

(SEKk)	2014-12-31	2013-12-31
EQUITY AND LIABILITIES		
Equity		
Restricted equity		
Share capital	52 900	52 705
Total restricted equity	52 900	52 705
Non restricted equity		
Share premium reserve	215 113	214 529
Profit/loss brought forward	-20 719	-14 485
Accumulated loss for the period	-1 716	-6 235
Total non restricted equity	192 679	193 809
Total equity	245 578	246 514
Non-current liabilities		
Current liabilities		
Accounts payable	71	100
Other payables	777	928
Accrued expenses and deferred income	1 555	3 625
Total liabilities	2 403	4 653
TOTAL EQUITY AND LIABILITIES	247 981	251 167
Pledged assets	-	-
Contingent liabilities	-	-

The parent company's changes in equity

(SEKk)	RESTRICTED EQUITY		NONE RESTRICTED EQUITY		
	Share capital	Share premium reserve	Profit/loss brought forward	Accumulated loss for the period	Total equity
Closing balance Dec 31 2012	52 705	214 529	-12 990	-1 495	252 749
Result for the period Jan - Dec 2013	-	-	-	-6 235	-6 235
Accounting of loss 2012	-	-	-1 495	1 495	-
Closing balance Dec 31 2013	52 705	214 529	-14 485	-6 235	246 514
Closing balance Dec 31 2013	52 705	214 529	-14 485	-6 235	246 514
Result for the period Jan - Dec 2014	-	-	-	-1 716	-1 716
Accounting of loss 2013	-	-	-6 235	6 235	-
New Share issue	195	585	-	-	780
Closing balance Dec 31 2014	52 900	215 113	-20 719	-1 716	245 578

Cash flow statement for the parent company

(SEKk)	Oct - Dec 2014	Oct - Dec 2013	Jan - Dec 2014	Jan - Dec 2013
Current operations				
Profit / loss after financial items	-547	-2 743	-1 716	-6 235
Adjustments for non-cash flow items				
Other non-cash flow items	-	-	-	-
Cash flow from current operations before income tax	-547	-2 743	-1 716	-6 235
Income tax paid	-	-	-	-
Cash flow from working capital changes				
Change in trade, other receivables and current assets	-1 368	4 279	3 242	4 495
Change in trade, other payables and other current liabilities	593	-89	-2 250	1 080
Cash flow from current operations	-1 322	1 447	-723	-659
Investment activities				
Investments	-	-	-	-
Cash flow from investment activities	-	-	-	-
Financing activities				
New issue	-	-	780	-
Loan from shareholders	-	-	-	-
Transaction costs new issue	-	-	-	-
Shareholders contribution & group contribution	-	-	-	-
Cash flow from financing activities	-	-	780	-
Cash flow for the period	-1 322	1 447	57	-659
Cash and cash equivalents at beginning of period	8 974	6 149	7 595	8 254
Cash and cash equivalents at end of period	7 652	7 595	7 652	7 595



Affibody Medical AB (publ) (556714-5601)
Gunnar Asplunds Allé 24
SE-171 63 Solna, Sweden

E-mail: reception@affibody.com
Phone: +46 (0) 8 59 88 38 00

www.affibody.com

Graphic design: Plucera Webbyrå (www.plucera.se)